Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SBP002
MIFTS: 41

Subependymal Glioma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Subependymal Glioma

About this section

MalaCards integrated aliases for Subependymal Glioma:

Name: Subependymal Glioma 12 15 73
Mixed Subependymoma-Ependymoma 12
Who Grade I Ependymal Tumor 12
Subependymal Astrocytoma 12
Glioma, Subependymal 44

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4843
MeSH 44 D018315
NCIt 50 C3795
SNOMED-CT 68 189910001 4553004
UMLS 73 C0206725
Sources

Summaries for Subependymal Glioma

About this section
MalaCards based summary : Subependymal Glioma, also known as mixed subependymoma-ependymoma, is related to subependymoma and tuberous sclerosis, and has symptoms including headache, motor manifestations and sensory manifestations. An important gene associated with Subependymal Glioma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are Neuroscience and Angiopoietin Like Protein 8 Regulatory Pathway. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and kidney, and related phenotype is behavior/neurological.

Sources

Related Diseases for Subependymal Glioma

About this section

Diseases related to Subependymal Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 subependymoma 30.5 ENO2 GFAP SYP TSC2
2 tuberous sclerosis 28.1 GFAP MTOR SYP TSC1 TSC2
3 subependymal giant cell astrocytoma 26.6 ENO2 GFAP MTOR SYP TSC1 TSC2
4 hepatic angiomyolipoma 10.7 MTOR TSC2
5 adult hepatocellular carcinoma 10.6 TSC1 TSC2
6 multilocular clear cell renal cell carcinoma 10.6 TSC1 TSC2
7 tuberous sclerosis 1 10.6 TSC1 TSC2
8 lissencephaly with cerebellar hypoplasia 10.6 TSC1 TSC2
9 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.5 TSC1 TSC2
10 corneal dystrophy, fleck 10.5 TSC1 TSC2
11 hemimegalencephaly 10.5 GFAP MTOR
12 perivascular epithelioid cell tumor 10.4 SYP TSC2
13 alexander disease 10.3 GFAP MTOR
14 polycystic liver disease 1 with or without kidney cysts 10.3 TSC1 TSC2
15 breast papillary carcinoma 10.2 SYP TSC2
16 desmoplastic infantile ganglioglioma 10.2 GFAP SYP
17 extraventricular neurocytoma 10.2 GFAP SYP
18 lung combined type small cell carcinoma 10.2 GFAP SYP
19 cellular ependymoma 10.2 GFAP SYP
20 kidney angiomyolipoma 10.2 MTOR TSC1 TSC2
21 gangliocytoma 10.2 GFAP SYP
22 kidney benign neoplasm 10.2 MTOR TSC1 TSC2
23 rhabdoid meningioma 10.2 GFAP SYP
24 focal cortical dysplasia, type ii 10.2 MTOR TSC1 TSC2
25 pilomyxoid astrocytoma 10.2 GFAP SYP
26 angiomyolipoma 10.2 MTOR TSC1 TSC2
27 tuberous sclerosis 2 10.2 MTOR TSC1 TSC2
28 chordoid meningioma 10.2 GFAP SYP
29 polycystic kidney disease 1 with or without polycystic liver disease 10.2 MTOR TSC1 TSC2
30 lymphangioleiomyomatosis 10.2 MTOR TSC1 TSC2
31 chiari malformation 10.2 GFAP SYP
32 dysembryoplastic neuroepithelial tumor 10.2 GFAP SYP
33 focal epilepsy 10.2 MTOR TSC1 TSC2
34 autosomal dominant polycystic kidney disease 10.2 MTOR TSC1 TSC2
35 angiocentric glioma 10.2 GFAP SYP
36 obstructive hydrocephalus 10.2 GFAP SYP
37 medulloepithelioma 10.2 GFAP SYP
38 megalencephaly 10.2 MTOR TSC1
39 anaplastic ependymoma 10.2 GFAP SYP
40 childhood oligodendroglioma 10.1 GFAP SYP
41 tanycytic ependymoma 10.1 GFAP SYP
42 pleomorphic xanthoastrocytoma 10.1 GFAP SYP
43 pineoblastoma 10.1 GFAP SYP
44 papilloma of choroid plexus 10.1 GFAP SYP
45 glioma 10.1
46 binswanger's disease 10.1 GFAP SYP
47 cerebellopontine angle tumor 10.1 GFAP SYP
48 giant cell glioblastoma 10.0 GFAP SYP
49 peutz-jeghers syndrome 10.0 TSC1 TSC2
50 infratentorial cancer 10.0 GFAP SYP

Graphical network of the top 20 diseases related to Subependymal Glioma:



Diseases related to Subependymal Glioma
Sources

Symptoms & Phenotypes for Subependymal Glioma

About this section

UMLS symptoms related to Subependymal Glioma:


headache, motor manifestations, sensory manifestations

MGI Mouse Phenotypes related to Subependymal Glioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.1 ENO2 GFAP MTOR SYP TSC1 TSC2
Sources

Drugs & Therapeutics for Subependymal Glioma

About this section

Drugs for Subependymal Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Dopamine Approved Phase 3,Not Applicable 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Analgesics Phase 3
7 Central Nervous System Depressants Phase 3
8 Adjuvants, Anesthesia Phase 3
9 Central Nervous System Stimulants Phase 3,Phase 2
10 Cholinergic Agents Phase 3,Phase 2
11 Cholinesterase Inhibitors Phase 3,Phase 2
12 Narcotics Phase 3
13 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3
16 Nootropic Agents Phase 3,Phase 2
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Peripheral Nervous System Agents Phase 3
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Dopamine Agents Phase 3,Not Applicable
22 Neurotransmitter Uptake Inhibitors Phase 3
23 Dexmethylphenidate Hydrochloride Phase 3
24 Dopamine Uptake Inhibitors Phase 3
25 Cola Nutraceutical Phase 3,Phase 1
26
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
27
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
28
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
31
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
32
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
33
Tamoxifen Approved Phase 2 10540-29-1 2733526
34
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
35
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
36
Bevacizumab Approved, Investigational Phase 2 216974-75-3
37
Armodafinil Approved, Investigational Phase 2 112111-43-0
38
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
40
Acetaminophen Approved Phase 2 103-90-2 1983
41
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
42
Promethazine Approved, Investigational Phase 2 60-87-7 4927
43
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
44
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
45
Doxil Approved June 1999 Phase 2 31703
46 Alkylating Agents Phase 2,Phase 1
47 Antineoplastic Agents, Alkylating Phase 2,Phase 1
48 cadexomer iodine Phase 1, Phase 2,Phase 2
49 Muromonab-CD3 Phase 2
50 Imatinib Mesylate Phase 2,Phase 1 220127-57-1 123596

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
5 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
6 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
7 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
8 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
9 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
10 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
11 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
12 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
13 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
14 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
15 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
16 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
17 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
18 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
19 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
20 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
21 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
22 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
23 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
24 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
25 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
26 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
27 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
28 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
29 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
30 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
31 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
32 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
33 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
34 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Recruiting NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
35 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
36 Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Terminated NCT00003567 Phase 1 O6-benzylguanine;carmustine;temozolomide
37 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
38 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
39 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
40 Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders Completed NCT00255671
41 Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma Completed NCT00005082 Not Applicable
42 Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting NCT01165632 Not Applicable fluorine F 18 fluorodopa
43 Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma Terminated NCT00430079 Not Applicable etanidazole
44 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable
45 Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors Withdrawn NCT00005790 Not Applicable

Search NIH Clinical Center for Subependymal Glioma

Cochrane evidence based reviews: glioma, subependymal

Sources

Genetic Tests for Subependymal Glioma

About this section
Sources

Anatomical Context for Subependymal Glioma

About this section

MalaCards organs/tissues related to Subependymal Glioma:

41
Brain, Liver, Kidney, Spinal Cord, Bone
Sources

Publications for Subependymal Glioma

About this section

Articles related to Subependymal Glioma:

# Title Authors Year
1
[Histogenesis of subependymal glioma in Bourneville's tuberous sclerosis]. ( 2346568 )
1990
2
PAPILLARY SUBEPENDYMAL GLIOSIS (GLIOMATOSIS) ASSOCIATED WITH VON RECKLINGHAUSEN'S DISEASE AND SUBEPENDYMAL GLIOMA. ( 14063111 )
1963
3
Subependymal glioma with hypertension: diagnostic problem. ( 14371747 )
1955
Sources

Variations for Subependymal Glioma

About this section
Sources

Expression for Subependymal Glioma

About this section
Search GEO for disease gene expression data for Subependymal Glioma.
Sources

Pathways for Subependymal Glioma

About this section

Pathways related to Subependymal Glioma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
12.35 ENO2 GFAP SYP
2
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.29 MTOR TSC1 TSC2
3
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.26 MTOR TSC1 TSC2
4
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.2 MTOR TSC1 TSC2
5
mTOR signalling 66
Show member pathways
 12.18 MTOR TSC1 TSC2
6
Phospholipase D signaling pathway 37
Show member pathways
 12.16 MTOR TSC1 TSC2
7
Type I Interferon Signaling Pathways 65
Show member pathways
 12.05 MTOR TSC1 TSC2
8
Translational Control 4
12.02 MTOR TSC1 TSC2
9
AMPK Enzyme Complex Pathway 64
Show member pathways
 11.96 MTOR TSC1 TSC2
10
AKT Signaling Pathway 67
11.92 MTOR TSC1 TSC2
11
Cellular senescence (KEGG) 37
11.9 MTOR TSC1 TSC2
12
Integrated Breast Cancer Pathway 1
11.87 MTOR TSC1 TSC2
13
Longevity regulating pathway 37
Show member pathways
 11.85 MTOR TSC1 TSC2
14
Autophagy Pathway 65
Show member pathways
 11.83 MTOR TSC1 TSC2
15
Autophagy - animal 37
11.74 MTOR TSC1 TSC2
16
Development IGF-1 receptor signaling 22
Show member pathways
 11.71 MTOR TSC1 TSC2
17
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.68 MTOR TSC1 TSC2
18
Glioblastoma Multiforme 64
11.63 MTOR TSC1 TSC2
19
TP53 Regulates Metabolic Genes 66
11.47 MTOR TSC1 TSC2
20
TBC/RABGAPs 66
11.3 TSC1 TSC2
21
ATM Signaling Network in Development and Disease 1
11.29 MTOR TSC2
22
mTOR signaling pathway (Pathway Interaction Database) 1
11.22 MTOR TSC1 TSC2
23
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.07 MTOR TSC2
24
Wnt Signaling Pathway Netpath 1
11.06 MTOR TSC1 TSC2
25
Follicle Stimulating Hormone (FSH) signaling pathway 1
11.01 MTOR TSC2
26
4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression 1
10.79 MTOR TSC1
27
LKB1 signaling events 1
10.76 MTOR TSC1 TSC2
28
BDNF-TrkB Signaling 1
10.33 MTOR TSC1 TSC2
Sources

GO Terms for Subependymal Glioma

About this section

Cellular components related to Subependymal Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosome GO:0005764 9.13 GFAP MTOR TSC2
2 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Subependymal Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.5 MTOR TSC1 TSC2
2 positive regulation of stress fiber assembly GO:0051496 9.48 MTOR TSC1
3 regulation of protein kinase activity GO:0045859 9.46 MTOR TSC1
4 negative regulation of TOR signaling GO:0032007 9.43 TSC1 TSC2
5 negative regulation of insulin receptor signaling pathway GO:0046627 9.4 TSC1 TSC2
6 positive regulation of macroautophagy GO:0016239 9.37 TSC1 TSC2
7 negative regulation of macroautophagy GO:0016242 9.26 MTOR TSC1
8 positive regulation of glial cell proliferation GO:0060252 9.16 GFAP MTOR
9 anoikis GO:0043276 8.96 MTOR TSC2
10 negative regulation of cell size GO:0045792 8.62 MTOR TSC1

Molecular functions related to Subependymal Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp90 protein binding GO:0051879 8.96 TSC1 TSC2
2 binding GO:0005488 8.8 MTOR TSC1 TSC2
Sources

Sources for Subependymal Glioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....